Press Release Covis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPD Zug, Switzerland, October 25, 2022 – Covis Pharma Group (“Covis”), a global...
Press Release Covis Pharma Reports on FDA Advisory Committee Hearing for Makena® Zug, Switzerland, 19 October 2022 – Covis Pharma Group (the “Company”), today reported that the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee to the U.S. Food and Drug...
Press Release Covis Pharma Group Announces Executive Leadership Appointment in Canada Zug, Switzerland, 14 July 2022 – Covis Pharma Group (the “Company”), a global specialty pharmaceutical company that markets therapeutic solutions for patients with...
Press Release Covis Pharma Provides Update on FDA Public Hearing for Makena® Zug, Switzerland, June 14, 2022 – Covis Pharma GmbH, an affiliate of Group S.à r.l. (collectively, “Covis”), announced today that the U.S. Food & Drug Administration (FDA) anticipates...
Press Release Covis Pharma Group Announces Two Executive Management Team Appointments – Michelle Lock Joins Covis Pharma as Chief Operating Officer. – Also Announces Executive Leadership Transition with the Appointment of Sandy Loreaux as President, U.S. Business....
Press Release Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines from AstraZeneca – Enters into on an Exclusive Promotion and Distribution Agreement with Novartis for Distribution Rights to Seebri® Breezhaler® and Ultibro® Breezhaler®...
Click here for Canada website